HLA Triple-Knockout Follicle Cells for Scar-Reducing Hair Implantation

The patent applies the 'Taking out' principle by removing the harmful HLA-a/b/c genes from the hair follicle stem cells through CRISPR/Cas9-mediated gene knockout. This extraction of the immunogenic components eliminates the primary cause of immune rejection, allowing the transplanted cells to survive and function in the recipient without attacking by the recipient's immune system, thereby resolving the contradiction between transplantation success and genetic modification complexity.

The patent converts the harmful effect of HLA genes (causing immune rejection) into a benefit by using their presence as a target for knockout. The CRISPR/Cas9 system is designed to specifically recognize and eliminate HLA-a/b/c gene expression, transforming the immunogenicity problem into a solution where the absence of these genes becomes the advantage for successful transplantation and long-term survival of the engineered cells.

The patent replaces the mechanical hair implantation system (which involves physically extracting and transplanting hair follicles, causing trauma, scarring, and hair loss) with a cellular therapy system. Hair follicle stem cells are cultured in vitro and then transplanted as a cell suspension, eliminating the mechanical trauma associated with traditional methods. This substitution resolves the contradiction by reducing harmful physical effects while maintaining or improving treatment efficiency through scalable cell production.

The patent changes the fundamental parameter of transplantation from whole hair follicle units to individual stem cells. This parameter change allows for a minimally invasive delivery method where cells are injected as a suspension rather than requiring large incisions for follicle extraction and implantation. The stem cells then naturally differentiate and form hair follicles, significantly reducing scarring and hair loss while improving overall treatment outcomes and efficiency.

The patent applies 'Preliminary action' by performing all necessary HLA-a/b/c gene knockouts and biosensor integration during the in vitro cell culture and expansion phase, before transplantation. The CRISPR/Cas9 editing is completed while cells are being propagated, allowing parallel processing of gene modification and cell expansion. This preliminary completion of genetic modifications eliminates time delays that would occur if editing were performed after transplantation, thus improving immune compatibility without significantly extending the overall treatment timeline.

The patent maintains continuous useful action by integrating the gene knockout process with the cell culture workflow. Rather than separating gene editing and cell expansion into distinct sequential phases, the system performs CRISPR/Cas9-mediated HLA gene elimination concurrently with stem cell propagation. The biosensor system continuously monitors cell health and differentiation status throughout the process, ensuring that the continuous culture and editing operations maintain cell viability and functionality, thereby achieving triple knockout without proportionally increasing development time.